Overview

A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)

Status:
Not yet recruiting

Trial end date:
2027-12-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy and safety and establish a preliminary recommended Phase 2 dose (RP2D) of MK-6598 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adult participants with advanced or metastatic solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Treatments:

Pembrolizumab